PDMS and PFO is effective as tamponade

Article

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

A study published in Clinical Ophthalmology has proved the efficacy of using polydimethyloxane (PDMS) and perfluoro-n-octane (PFO) as tamponade in patients with retinal detachment complicated by proliferative vitreoretinopathy (PVR).

An investigation led by Dr Stefano Zenoni, Bergamno Hospital, Bergamo, Italy, aimed to evaluate ocular tolerance and efficacy of short-term tamponade with double-filling of PDMS and perfluoro-n-octane (PFO) in 30 patients. Double filling with 30% PFO and 70% PDMS was performed for a mean period of 23 days. Follow-up visits were scheduled for 1 week, 1 month and 3 months postoperatively. The main outcome measures included visual acuity, intraocular pressure (IOP), PVR reprofileration and electrophysiological parameters.

Of the 30 patients, 14 experienced improved postoperative visual acuity, 12 patients maintained preoperative visual acuity and 4 patients had a decrease in visual acuity. The average postoperative IOP was 19.7 mmHg. Nine patients experienced an increase in IOP, which was later treated with topical drops or systematic carbonic anhydrase.

Additionally, the researchers found a statistically significant difference in the data obtained with the electroretinogram (ERG) between week 4 and 8 of the follow-up period. There were no electroretinographic traces of retinal toxicity and there was a low occurrence of PVR reproliferation.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.